Mozobil Inj, 1.2ml

Plerixafor is a CXCR4 chemokine receptor antagonist. It blocks the binding of stromal cell-derived factor-1 alpha (SDF-1α) to the CXCR4 receptor. This interaction is crucial for the homing and retention of hematopoietic stem cells (HSCs) in the bone marrow. By blocking CXCR4, plerixafor disrupts the SDF-1α/CXCR4 axis, leading to the rapid mobilization of CD34+ hematopoietic stem cells from the bone marrow into the peripheral blood.

Urgent Side Effects: Seek Medical Help Right Away

While rare, some people may experience severe and potentially life-threatening side effects when taking this medication. Immediately contact your doctor or seek medical attention if you experience any of the following symptoms, which may indicate a serious allergic reaction:

Rash, hives, itching, or red, swollen, blistered, or peeling skin, with or without fever
Wheezing, tightness in the chest or throat, trouble breathing, swallowing, or talking
Unusual hoarseness or swelling of the mouth, face, lips, tongue, or throat

Some allergic reactions can be life-threatening. Additionally, seek medical help right away if you experience:

Severe dizziness or fainting
Unexplained bruising or bleeding
Left upper stomach pain or shoulder pain, as this may indicate an enlarged spleen, which can lead to rupture

Other Possible Side Effects

Like all medications, this drug can cause side effects, although many people may not experience any or may only have mild symptoms. If you are bothered by any of the following side effects or if they do not go away, contact your doctor or seek medical help:

Dizziness, tiredness, or weakness
Headache
Diarrhea, stomach pain, upset stomach, or vomiting
Gas
Joint pain
Irritation at the injection site
* Trouble sleeping

This is not an exhaustive list of possible side effects. If you have questions or concerns about side effects, consult your doctor. You can also report side effects to the FDA at 1-800-332-1088 or online at https://www.fda.gov/medwatch.

Before Taking This Medication: Important Information to Share with Your Doctor

It is essential to inform your doctor about the following:

Any allergies you have, including allergies to this medication, its components, or other substances. Be sure to describe the allergic reaction you experienced, including any symptoms that occurred.
If you have been diagnosed with leukemia.
If you are breastfeeding. You should not breastfeed while taking this medication and for 1 week after your last dose.

This medication may interact with other medications or health conditions. Therefore, it is crucial to provide your doctor and pharmacist with a comprehensive list of:
All prescription and over-the-counter medications you are taking
Any natural products or vitamins you are using
Your medical history, including any health problems you have

Before starting, stopping, or changing the dose of any medication, including this one, you must consult with your doctor to ensure your safety.

It is essential to inform all your healthcare providers, including doctors, nurses, pharmacists, and dentists, that you are taking this medication. To minimize the risk of dizziness or fainting, get up slowly from a sitting or lying down position, and exercise caution when climbing stairs.

Regular blood tests and other laboratory assessments should be conducted as directed by your doctor to monitor your condition.

This medication may pose a risk to an unborn baby. Therefore, a pregnancy test will be administered before initiating treatment to confirm that you are not pregnant. If you or your partner could become pregnant, it is crucial to use effective birth control methods during treatment and for a specified period after the final dose. Consult your doctor to determine the recommended duration of birth control use. If pregnancy occurs, notify your doctor immediately.

• Myelosuppressive agents (concurrent use may exacerbate myelosuppression, though plerixafor is used in this context)
• Drugs that affect renal function (may alter plerixafor clearance)

• Injection site reactions (redness, swelling, pain)
• Gastrointestinal symptoms (diarrhea, nausea, vomiting, abdominal pain)
• Fatigue
• Dizziness
• Headache
• Musculoskeletal pain
• Signs of hypersensitivity reaction (rash, urticaria, dyspnea, facial swelling)
• Signs of splenic enlargement or rupture (left upper quadrant abdominal pain, shoulder pain, rapid breathing, pallor)

Plerixafor may cause fetal harm when administered to a pregnant woman. Animal studies have shown adverse effects on embryo-fetal development. Use during pregnancy is generally not recommended unless the potential benefit justifies the potential risk to the fetus.

It is not known whether plerixafor is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in breastfed infants, a decision should be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of the drug to the mother.

Approved for pediatric patients with Non-Hodgkin Lymphoma (NHL) and acute lymphoblastic leukemia (ALL) for stem cell mobilization. Dosing is weight-based (0.24 mg/kg) and similar to adults, with renal dose adjustments as needed. Safety and efficacy in children <1 year of age have not been established.

No overall differences in safety or effectiveness were observed between elderly patients (≥65 years) and younger patients. No specific dose adjustment is required based on age alone, but renal function should be assessed as elderly patients are more likely to have decreased renal function.

• Plerixafor is always used in combination with G-CSF for stem cell mobilization, not as monotherapy.
• Timing is crucial: Plerixafor should be administered 6-11 hours prior to the start of apheresis.
• Monitor CD34+ cell counts closely to determine the optimal timing and number of apheresis sessions.
• Patients should be monitored for signs and symptoms of splenic enlargement or rupture, especially those with pre-existing splenic conditions or those receiving high doses of G-CSF.
• There is a theoretical risk of tumor cell mobilization in patients with leukemia; however, clinical studies have not shown an increased risk of relapse in patients with NHL or MM.
• Patients with a history of cardiac risk factors should be monitored for cardiac events, though these are rare.

• Granulocyte-colony stimulating factor (G-CSF) alone (e.g., filgrastim, pegfilgrastim)
• Chemotherapy-based mobilization regimens (e.g., cyclophosphamide with G-CSF)

If your symptoms or health problems do not improve or worsen over time, it is essential to contact your doctor for further evaluation and guidance.

To ensure safe use, do not share your medication with others, and never take someone else's medication. Store all medications in a secure location, out of reach of children and pets, to prevent accidental ingestion.

Proper disposal of unused or expired medications is crucial. Do not dispose of them by flushing down the toilet or pouring down the drain unless specifically instructed to do so. If you are unsure about the correct disposal method, consult your pharmacist for guidance. Many communities have drug take-back programs, which your pharmacist can help you locate.

Some medications may come with an additional patient information leaflet. Check with your pharmacist to see if this applies to your prescription. If you have any questions or concerns about your medication, do not hesitate to discuss them with your doctor, nurse, pharmacist, or other healthcare provider.

In the event of a suspected overdose, immediately call your local poison control center or seek emergency medical attention. Be prepared to provide information about the medication taken, the amount, and the time it occurred, as this will aid in providing appropriate treatment.